Butorphanol Nasal Spray CIV
Generic Name and Formulations:
Butorphanol tartrate 1mg/spray; nasal spray.
Various generic manufacturers
Indications for Butorphanol Nasal Spray:
Pain management when opioid analgesia is appropriate.
≥18 years: initially 1 spray in 1 nostril, repeat after 60–90 minutes if needed (Elderly: 90–120 minutes); may repeat in 3–4 hours. Or, may give 1 spray in each nostril, may repeat after 3–4 hours.
<18 years: not recommended.
Head injury. Increased intracranial pressure. Biliary tract surgery. Respiratory, cardiac, renal, or hepatic dysfunction. MI. Ventricular dysfunction. Coronary insufficiency. Hypertension. May precipitate withdrawal in narcotic addicts. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Nasal vasoconstrictors delay onset. May be antagonized by concomitant (within 30 minutes) sumatriptan nasal spray.
Sedation, dizziness, nasal congestion, insomnia, GI upset, respiratory depression, sweating, hypo- or hypertension, rash, vasodilation, palpitation, tinnitus, respiratory and CNS effects.
Formerly known under the brand name Stadol NS.
Nasal Spray 2.5mL (8–15 sprays)—Contact supplier.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|